Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396397 | 1.00 | HTR1D (0.53) | HTR1DHTR2CHTR1ACA2MAOB | |
| Hydrochloric Acid SCHEMBL30297758 | 0.98 | HTR1D (0.51) | HTR1DHTR2CHTR1ACA2MAOB | |
| Hydrochloric Acid SCHEMBL20542639 | 0.98 | HTR1D (0.51) | HTR1DHTR2CHTR1ACA2MAOB | |
| SCHEMBL5237537 | 0.89 | CA2 (0.49) | HTR1DHTR2CHTR1ACA2MAOB | |
| SCHEMBL5235143 | 0.87 | CA2 (0.47) | HTR1DHTR2CHTR1ACA2MAOB | |
| SCHEMBL30824566 | 0.83 | CA2 (0.54) | CA2MAOBCYP2A6CYP17A1CYP19A1 | |
| SCHEMBL6795368 | 0.83 | CA2 (0.54) | CA2MAOBCYP2A6CYP17A1CYP19A1 | |
| Hydrochloric Acid SCHEMBL15818713 | 0.82 | CA2 (0.53) | CA2MAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7360353 | 0.80 | MAOB (0.50) | HTR1ACA2MAOBCYP17A1CYP19A1 | |
| SCHEMBL734528 | 0.80 | MAOB (0.50) | HTR1ACA2MAOBCYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068602-A2 | PRODUCTION AND MEDICAL USE OF PSILOCYBIN AND RELATED COMPOUNDS | PSYLINK UAB (LT) | 2025-04-03 | — | — | WO | claimed |
| CN-110922412-A | Asymmetric synthesis method of medicinal compound with antipsychotic effect | 复旦大学 | 2020-03-27 | — | — | CN | claimed |
| WO-2023202582-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-11713325-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2023-08-01 | — | — | US | disclosed |
| CN-115720578-A | Tricyclic derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4101855-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| WO-2021214126-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-10-28 | — | — | WO | disclosed |
| CN-111116598-A | Asymmetric synthesis method of antipsychotic drugs | 复旦大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-0214556-A1 | Substituted hexahydro-arylquinolizine derivatives, processes for their preparation and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0204254-A2 | Substituted hexahydro arylquinolizines, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0154142-A1 | Substituted hexahydro arylquinolizines | MERCK & CO. INC. (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0024587-B1 | PROPENYLAMINES, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (CH) | 1984-11-14 | — | — | EP | disclosed |
| EP-0009780-B1 | OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4260761-A | Intermediates for the preparation of octahydro-1H-benzo[4,5]furo[3,2,-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0024587-A1 | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals | SANDOZ AG (CH) | 1981-03-11 | — | — | EP | disclosed |
| US-4243668-A | Octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0009780-A2 | Octahydro-1H-benzo(4,5)furo(3,2-e)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713325-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | HTR1D 4565/4885HTR2C 4741/4885HTR1A 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.